Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy

NCT04266795 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT04266795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04266795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Lead sponsor
Takeda
Phase
Phase 2
Overall status
Completed
Start date
October 13, 2020
Completion date
October 6, 2025
Enrollment
164 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml)